Interestingly, only addition of low-dose everolimus (mTORC1 inhibitor) to anti-PD-1 led to better bladder or cervical cancer control124,125, while addition of high-dose everolimus to anti-PD-1 showed a trend towards worse tumour control124. The gene discussed is PDCD1; the disease is cervical carcinoma.